Advaxis has entered into a collaboration with Merck to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. The trial will evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study in patients with previously treated metastatic, castration-resistant prostate cancer.   Both ADXS-PSA and pembrolizumab are immunotherapies designed to enhanc...